fbpx

scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)

BURLINGTON, MA, November 2, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date of June 23, 2018.

about scpharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.

contacts
Investor Relations for scPharmaceuticals, Inc.:
Katherine Taudvin, 781-301-6706
ktaudvin@scpharma.com

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge